Neutralization assay for human group C rotaviruses using a reverse passive hemagglutination test for endpoint determination

Ritsushi Fujii, Mitsutaka Kuzuya, Masako Hamano, Hajime Ogura, Masao Yamada, Tadashige Mori

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A novel neutralization assay for human group C rotavirus (CHRV) was developed by using a reverse passive hemagglutination (RPHA) test for endpoint determination. In this assay, the neutralization (N)-RPHA test, serial twofold dilutions of sera were mixed with a solution of CHRV that yielded an RPHA test titer of 8 at 3 days after infection. The mixtures were incubated at 37°C for 1 h and were inoculated onto CaCo-2 cell monolayers in a 96-well microplate. Maintenance medium containing 100 μg of pancreatin per ml was placed in each well. The plate was sealed with sticky plastic film and was incubated at 37°C for 3 days under continuous rotation. Then, the RPHA test titer of each well was determined. The neutralization titer was expressed as the reciprocal of the maximum dilution of the serum that exhibited a fourfold (75%) or greater reduction in the RPHA test titer (8 to 2 or less). Seroconversion of neutralizing antibody was demonstrated by this method in four sets of paired serum specimens from patients with diarrheal disease caused by CHRV. The seroprevalence of CHRV in the general population in Okayama Prefecture was 26.8% by immunofluorescence and 25.5% by the N-RPHA test. The N-RPHA test described here is the first system used to assay for a neutralization antibody against CHRV and is applicable in both clinical and epidemiological settings.

Original languageEnglish
Pages (from-to)50-54
Number of pages5
JournalJournal of Clinical Microbiology
Volume38
Issue number1
Publication statusPublished - 2000

Fingerprint

Endpoint Determination
Hemagglutination Tests
Rotavirus
Serum
Pancreatin
Caco-2 Cells
Seroepidemiologic Studies
Neutralizing Antibodies
Plastics
Fluorescent Antibody Technique
Maintenance
Antibodies

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Neutralization assay for human group C rotaviruses using a reverse passive hemagglutination test for endpoint determination. / Fujii, Ritsushi; Kuzuya, Mitsutaka; Hamano, Masako; Ogura, Hajime; Yamada, Masao; Mori, Tadashige.

In: Journal of Clinical Microbiology, Vol. 38, No. 1, 2000, p. 50-54.

Research output: Contribution to journalArticle

Fujii, Ritsushi ; Kuzuya, Mitsutaka ; Hamano, Masako ; Ogura, Hajime ; Yamada, Masao ; Mori, Tadashige. / Neutralization assay for human group C rotaviruses using a reverse passive hemagglutination test for endpoint determination. In: Journal of Clinical Microbiology. 2000 ; Vol. 38, No. 1. pp. 50-54.
@article{0795ec8ffb6d40749b9bda4724fe6d8c,
title = "Neutralization assay for human group C rotaviruses using a reverse passive hemagglutination test for endpoint determination",
abstract = "A novel neutralization assay for human group C rotavirus (CHRV) was developed by using a reverse passive hemagglutination (RPHA) test for endpoint determination. In this assay, the neutralization (N)-RPHA test, serial twofold dilutions of sera were mixed with a solution of CHRV that yielded an RPHA test titer of 8 at 3 days after infection. The mixtures were incubated at 37°C for 1 h and were inoculated onto CaCo-2 cell monolayers in a 96-well microplate. Maintenance medium containing 100 μg of pancreatin per ml was placed in each well. The plate was sealed with sticky plastic film and was incubated at 37°C for 3 days under continuous rotation. Then, the RPHA test titer of each well was determined. The neutralization titer was expressed as the reciprocal of the maximum dilution of the serum that exhibited a fourfold (75{\%}) or greater reduction in the RPHA test titer (8 to 2 or less). Seroconversion of neutralizing antibody was demonstrated by this method in four sets of paired serum specimens from patients with diarrheal disease caused by CHRV. The seroprevalence of CHRV in the general population in Okayama Prefecture was 26.8{\%} by immunofluorescence and 25.5{\%} by the N-RPHA test. The N-RPHA test described here is the first system used to assay for a neutralization antibody against CHRV and is applicable in both clinical and epidemiological settings.",
author = "Ritsushi Fujii and Mitsutaka Kuzuya and Masako Hamano and Hajime Ogura and Masao Yamada and Tadashige Mori",
year = "2000",
language = "English",
volume = "38",
pages = "50--54",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Neutralization assay for human group C rotaviruses using a reverse passive hemagglutination test for endpoint determination

AU - Fujii, Ritsushi

AU - Kuzuya, Mitsutaka

AU - Hamano, Masako

AU - Ogura, Hajime

AU - Yamada, Masao

AU - Mori, Tadashige

PY - 2000

Y1 - 2000

N2 - A novel neutralization assay for human group C rotavirus (CHRV) was developed by using a reverse passive hemagglutination (RPHA) test for endpoint determination. In this assay, the neutralization (N)-RPHA test, serial twofold dilutions of sera were mixed with a solution of CHRV that yielded an RPHA test titer of 8 at 3 days after infection. The mixtures were incubated at 37°C for 1 h and were inoculated onto CaCo-2 cell monolayers in a 96-well microplate. Maintenance medium containing 100 μg of pancreatin per ml was placed in each well. The plate was sealed with sticky plastic film and was incubated at 37°C for 3 days under continuous rotation. Then, the RPHA test titer of each well was determined. The neutralization titer was expressed as the reciprocal of the maximum dilution of the serum that exhibited a fourfold (75%) or greater reduction in the RPHA test titer (8 to 2 or less). Seroconversion of neutralizing antibody was demonstrated by this method in four sets of paired serum specimens from patients with diarrheal disease caused by CHRV. The seroprevalence of CHRV in the general population in Okayama Prefecture was 26.8% by immunofluorescence and 25.5% by the N-RPHA test. The N-RPHA test described here is the first system used to assay for a neutralization antibody against CHRV and is applicable in both clinical and epidemiological settings.

AB - A novel neutralization assay for human group C rotavirus (CHRV) was developed by using a reverse passive hemagglutination (RPHA) test for endpoint determination. In this assay, the neutralization (N)-RPHA test, serial twofold dilutions of sera were mixed with a solution of CHRV that yielded an RPHA test titer of 8 at 3 days after infection. The mixtures were incubated at 37°C for 1 h and were inoculated onto CaCo-2 cell monolayers in a 96-well microplate. Maintenance medium containing 100 μg of pancreatin per ml was placed in each well. The plate was sealed with sticky plastic film and was incubated at 37°C for 3 days under continuous rotation. Then, the RPHA test titer of each well was determined. The neutralization titer was expressed as the reciprocal of the maximum dilution of the serum that exhibited a fourfold (75%) or greater reduction in the RPHA test titer (8 to 2 or less). Seroconversion of neutralizing antibody was demonstrated by this method in four sets of paired serum specimens from patients with diarrheal disease caused by CHRV. The seroprevalence of CHRV in the general population in Okayama Prefecture was 26.8% by immunofluorescence and 25.5% by the N-RPHA test. The N-RPHA test described here is the first system used to assay for a neutralization antibody against CHRV and is applicable in both clinical and epidemiological settings.

UR - http://www.scopus.com/inward/record.url?scp=0033987916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033987916&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 50

EP - 54

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 1

ER -